FDA approved Pfizer-BioNTech’s XFG-adapted COMIRNATY formula for adults 65 and older and high-risk people aged 5 to 64 years.
News|Slideshows|May 26, 2021
5 Myths that Persist about COVID-19 Vaccines
Author(s)Grace Halsey
Truth: 67% of US unvaccinated adults believe or cannot judge the veracity of the 5 myths that follow. With more than half the population not fully vaccinated, there is more work to do.
Advertisement
The latest data from the Centers for Disease Control and Prevention show that 39.5% of the US population has been fully vaccinated against COVID-19; 49.5% has received at least one dose.
The reasons for not getting vaccinated are many and varied. A
The KFF analysis found that, overall, 67% of unvaccinated adults either believed or weren't sure about the truth of one of the 5 following longstanding myths.
Resources to help dispel vaccine myths
Advertisement
Related to this article
A Vaccine Integrity Project review found influenza, COVID-19, and RSV immunizations continue to protect against severe illness, hospitalization, and death.
Pre-existing antibodies to common microbes predicted COVID-19 vaccine response strength in healthy and immunosuppressed adults.
FDA approved bictegravir/lenacapavir for adults with suppressed HIV-1 and no known or suspected component resistance.
FDA expands dolutegravir dispersible tablets to children with HIV-1 weighing at least 2 kg, including eligible term newborns.
EADV 2026: Lebrikizumab improved hand and foot clearance, itch, and pain at 16 weeks versus placebo in a phase 3b atopic dermatitis trial.
EASD 2026: The combination of semaglutide/cagrilintide altered food-cue responses and showed a 22.4% estimated weight difference vs placebo; separate data found less organ fat in type 2 diabetes.
The FDA accepted Bayer's sNDA and granted Priority Review to elinzanetant for vasomotor symptoms in women on endocrine therapy for HR+ breast cancer.
Advertisement
Advertisement
Trending on Patient Care Online
1
CagriSema Alters Food-Cue Responses, Reduces Organ Fat in New Analyses
2
Beyond Semaglutide and Tirzepatide: The Next Wave of Obesity Medicines
3
FDA Grants Priority Review to Elinzanetant for VMS in HR+ Breast Cancer Patients on Endocrine Therapy
4
Lebrikizumab Improves Hand and Foot Atopic Dermatitis in Phase 3b Trial
5